Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.
Helena AebersoldFabienne Foster-WitassekStefanie AeschbacherJuerg H BeerEva BlozikManuel BlumLeo BonatiGiulio ConteMichael CoslovskyMaria Luisa De PernaMarcello Di ValentinoStefan FelderCarola A HuberGiorgio MoschovitisAndreas MuellerRebecca E PaladiniTobias ReichlinNicolas RodondiAnnina StauberChristian SticherlingThomas D SzucsDavid ConenMichael KuhneStefan OsswaldMatthias SchwenkglenksMiquel Serra-Burrielnull nullPublished in: Open heart (2024)
Applying a causal inference method to real-world data, we could not demonstrate switching to DOACs to be cost-effective for AF patients with at least 1 year of VKA treatment. Our estimates align with results from a previous randomised trial.
Keyphrases
- atrial fibrillation
- end stage renal disease
- study protocol
- ejection fraction
- newly diagnosed
- clinical trial
- randomized controlled trial
- venous thromboembolism
- prognostic factors
- electronic health record
- peritoneal dialysis
- big data
- single cell
- replacement therapy
- direct oral anticoagulants
- patient reported outcomes